Experts share what you need to know about GLP-1-related hair loss as the side-effect gets more attention from researchers About 20 million people across the US, UK, and EU are taking GLP-1 receptor agonists like tirzepatide and semaglutide (Ozempic or Mounjaro are common brands) for weight loss and type 2 diabetes. As their use has…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.